vTv Therapeutics Inc VTVT

NAS: VTVT | ISIN: US9183851057   15:30
27,90 USD (0,00%)
(0,00%)   15:30
Grafiek vTv Therapeutics Inc Grafiek vTv Therapeutics Inc

vTv Therapeutics Inc in het nieuws

19 maart 2024 · Cantex Pharmaceuticals To Present At 5Th Annual Glioblastoma Drug Development Summit · Persbericht

22 februari 2024 · CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE · Persbericht

27 september 2023 · Cantex And Michigan Medicine Announce Initiation Of A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Pivotal Clinical Trial To Evaluate The Safety And Efficacy Of Azeliragon In The Treatment Of Patients Hospitalized For Covid-19 · Persbericht

26 september 2023 · Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer · Persbericht

18 september 2023 · Cantex Pharmaceuticals And Lenox Hill Hospital Announce Initiation Of A Phase 2 Study Of Rage Inhibitor Azeliragon As A Front-Line Treatment For Unmethylated Glioblastoma · Persbericht

10 augustus 2023 · Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer · Persbericht

15 juni 2023 · Cantex Pharmaceuticals To Present At The Medinvest Oncology Investor Conference In Boston · Persbericht

20 april 2023 · Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19 · Persbericht

6 maart 2023 · Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases · Persbericht

27 februari 2023 · Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma · Persbericht

Profiel vTv Therapeutics Inc

Biotechnologie
Fabricage van farmaceutische preparaten
Gezondheidstechnologie
Productie

Website: vtvtherapeutics.com

Hoofdzetel: High Point, North Carolina vlag Verenigde Staten

CEO: Stephen Holcombe

Werknemers: 55

Aandelen vTv Therapeutics Inc

Beurswaarde: 67,88 miljoen USD

Effecten: 2,43 miljoen

Beta: 0,32

Mijn selecties